SGPP1 and plasma cell myeloma: Moreover, analysis of the GSE4581 dataset from the Arkansas myeloma database showed that, although there was no difference in survival through the first 29 months, afterwards (particularly from 34 months on), as the patients’ disease progressed, there was a strongly significant association of high SGPP1 levels with longer survival (p = 0.008; HR = 0.1506; n = 121) (Figure 2D).